-- 
SWISS DAYBOOK: Roche, Novartis, Metall Zug, Oridion, PubliGroupe

-- B y   E l e n a   L o g u t e n k o v a   a n d   K l a u s   W i l l e
-- 
2011-08-29T05:47:46Z

-- http://www.bloomberg.com/news/2011-08-29/swiss-daybook-roche-novartis-metall-zug-oridion-publigroupe.html
Rocheâ€™s experimental drug
dalcetrapib increased so-called good cholesterol without having
an effect on  blood pressure , a study showed.  EQUITIES:
*Novartis said U.S. regulators asked for additional clinical
data on the experimental gouty arthritis medicine ACZ885.
*Metall Zug said first-half sales increased to 409.5 million
Swiss francs ($506.9 million) from 397.8 million francs a year
earlier.
*Oridion Systems says first-half revenue was $31.3 million.
*PubliGroupe reports first half net profit of 15 million francs.  ECONOMY:
*SNB should boost  money supply  further to weaken the franc,
Swatch CEO Hayek tells Der Sonntag  MARKETS:
*The SMI rose 0.5 percent to 5,323.12.
*The SPI increased 0.4 percent to 4,844.58.
*The Stoxx Europe 600 Index fell 0.7 percent to 225.52.
*The MSCI Asia-Pacific Index rose 1.6 percent until 7:34 a.m.
Zurich time
*Euro-franc traded at 1.1748 at 7:35 a.m. Zurich time.  To contact the reporters on this story:
Elena Logutenkova in Zurich at 
 elogutenkova@bloomberg.net ;
Klaus Wille in Zurich at 
 kwille@bloomberg.net   To contact the editor responsible for this story:
Angela Cullen at 
 acullen8@bloomberg.net  